Dennis Charney – författare

Publisher's Note: Products purchased from Third Party sellers are not guaranteed by the publisher for quality, authenticity, or access to any online entitlements included with the product.A Clinically-Oriented, Prescriptive Guide to Diagnosing and Treating Mood DisordersDepression is very common in chronic medical illness, hindering recovery, increasing functional impairment, contributing to the costs of treating disease, and worsening prognosis. In addition, symptoms of depression are often indistinguishable from symptoms of co-occurring illnesses. It is imperative that clinicians acquire a more precise understanding of how depression and other chronic medical conditions impact each other, and how the treatments for each may influence the other.This book describes the epidemiology, etiology, diagnosis, and treatment of comorbid depression and bipolar disorder with specific illnesses. It informs physicians about what patients need for optimum outcomes, and gives practical ideas on communicating with patients and instilling hope.This wealth of practical information on treating mood disorders and comorbid physical illness over the long term and avoiding relapses can be immediately utilized to enrich patient care. This is the first step-by-step mood disorder guidebook designed specifically for physician use:Helps physicians detect, diagnose, and treat depression and bipolar disorders in a concise, results-oriented way. Also helps physicians understand the issues and concerns of their patients for more effective and patient-centered care.Provides a clinically rigorous method for quickly and accurately linking symptoms to each disorder.Offers clear, up-to-date information on psychotropic drugs--with definitive instructions on the use of these antidepressants and mood stabilizers in the treatment of disorders, including dosage guidelines.Covers mood disorders as primary illnesses.Focuses also on how mood disorders affect the diagnosis, treatment, and course of specific medical illnesses.

The Sixth Edition of Charney and Nestler's Neurobiology of Mental Illness builds on previous editions of the book and reflects the continuing progress in reintegrating psychiatry into the mainstream of modern biomedical science. This reintegration remains a work in progress, based on the unique complexity of the brain and its diseases. Yet, the research tools that are transforming other branches of medicine-epidemiology, genetics, epigenetics, molecular and cell biology, imaging, and medicinal chemistry, along with fundamental advances in the neurosciences that make it possible to decipher cell types and their larger circuits to an unprecedented degree, are now at long last transforming psychiatry. Collectively, the 75 chapters in this newly renovated textbook describe the developments in genetics and in molecular, cellular, and systems neuroscience that are breaking new ground in the diagnosis, treatment, and prevention of disabling psychiatric disorders. In this updated edition, Section 1 focuses on the major methodological approaches to studying the biological basis of mental illness. Sections 2 through 8 each focus on a major class of mental illness, including schizophrenia, bipolar disorder, depression, anxiety and trauma disorders, substance use disorders, neurodegenerative disorders, and childhood psychiatry disorders. The final section is a collection of essays that address what can be expected over the next decade in terms of improving psychiatric diagnosis, achieving a true precision approach to treating mental illness, along with new avenues of medication and non-medication therapies in the offing.

Therapies for Treatment-Resistant Depression: Neuropharmacology and Neurostimulation provides readers with an authoritative, comprehensive and targeted treatment guide. The first section reviews the essential knowledge and methods of clinical neuroscience and neuropsychopharmacological techniques as they apply to novel treatment discovery for depression. This is followed by detailed chapters on ketamine, esketamine, other glutamate modulators in development, GABA modulators, neuropeptides, anti-inflammatory agents, and other classes of novel therapeutics under study for TRD and related mood disorders.The last section consists of a set of chapters of special interest that includes current and future research directions, development of psilocybin-based interventions and other psychedelic compounds currently under study for TRD and advances in biomarker-guided and personalized treatment. Edited by world renowned experts in the field, this book is the ultimate resource for researchers and clinicians.

Defines treatment-resistant depression, including epidemiologyOutlines neuroimaging and brain-based biomarkers in treatment-resistant depression using patient dataReviews safety and monitoring protocols of ketamine in clinical care

Humans are remarkably resilient in the face of crises, traumas, disabilities, attachment losses and ongoing adversities. To date, most research in the field of traumatic stress has focused on neurobiological, psychological and social factors associated with trauma-related psychopathology and deficits in psychosocial functioning. Far less is known about resilience to stress and healthy adaptation to stress and trauma. This book brings together experts from a broad array of scientific fields whose research has focused on adaptive responses to stress. Each of the five sections in the book examines the relevant concepts, spanning from factors that contribute to and promote resilience, to populations and societal systems in which resilience is employed, to specific applications and contexts of resilience and interventions designed to better enhance resilience. This will be suitable for clinicians and researchers who are interested in resilience across the lifespan and in response to a wide variety of stressors.